热门资讯> 正文

Nasus Pharma 1H非GAAP每股收益为-0.54美元

2026-08-17 22:57

Nasus Pharma(NSRX) 0

Nasus Pharma Ltd. press release (NSRX): 1H Non-GAAP EPS of -$0.54.
Six months ended June 30, 2026, net loss totaled $5.94M.
Research and development expenses increased to $2.59M while general and administrative expenses rose to $3.45M.
Total cash, cash equivalents, and short-term deposits as of June 30, 2026, were $11.90M.

More on Nasus Pharma Ltd.

Seeking Alpha’s Quant Rating on Nasus Pharma Ltd.
Historical earnings data for Nasus Pharma Ltd.
Financial information for Nasus Pharma Ltd.

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。